Prof Katja Weisel speaks to ecancer about the results from phase III CANDOR study that she presented at the virtual EHA 2020 conference.
She outlines the design of the phase III study, which investigates the combination of carfilzomib, dexamethasone and daratumumab (KdD) versus carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM).
Prof Weisel presents the subgroup analysis of CANDOR by number of prior lines of therapy and prior therapies - including patient characteristics and safety profiles of these subgroups.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.